BBOT Key Statistics, Chart & Performance
The current stock price of BBOT is 13.14 USD. In the past month the price increased by 8.15%.
BBOT Latest News, Press Relases and Analysis
BBOT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.61 | 394.34B | ||
| AMGN | AMGEN INC | 14.69 | 172.98B | ||
| GILD | GILEAD SCIENCES INC | 14.8 | 150.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.46 | 112.15B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.62 | 73.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 843.18 | 56.81B | ||
| INSM | INSMED INC | N/A | 41.92B | ||
| NTRA | NATERA INC | N/A | 33.00B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.17 | 20.65B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.16B | ||
| INCY | INCYTE CORP | 15.06 | 18.98B |
Related stock screener links
About BBOT
Company Profile
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
Company Info
BRIDGEBIO ONCOLOGY THERAPEUT
256 E. Grand Avenue, Suite 104
South San Francisco CALIFORNIA US
Employees: 0
Phone: 18577020377
BRIDGEBIO ONCOLOGY THERAPEUT / BBOT FAQ
What does BBOT do?
Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in South San Francisco, California. The company went IPO on 2024-02-09. The firm is focused on advancing the pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. Its pipeline of RAS-targeted oncology drug candidates includes BBO-8520, BBO-10203, and BBO-11818. BBO-8520 (NCT06343402) is a direct inhibitor of KRASG12C in both the ON and OFF states that is being evaluated both as monotherapy and in combination with pembrolizumab in the Phase 1 ONKORAS-101 trial for patients with KRASG12C mutant non-small cell lung cancer. BBO-10203 (NCT06625775) is an orally bioavailable small molecule that selectively and specifically blocks the physical interaction between RAS and PI3Ka, resulting in the inhibition of RAS-driven PI3Ka-AKT signaling in tumors without the risk of hyperglycemia. BBO-11818 (NCT06917079) is a panKRAS inhibitor targeting mutant KRAS in both the ON and OFF states with strong potency against KRASG12D and KRASG12V mutants.
Can you provide the latest stock price for BRIDGEBIO ONCOLOGY THERAPEUT?
The current stock price of BBOT is 13.14 USD. The price decreased by -4.02% in the last trading session.
Does BRIDGEBIO ONCOLOGY THERAPEUT pay dividends?
BBOT does not pay a dividend.
How is the ChartMill rating for BRIDGEBIO ONCOLOGY THERAPEUT?
BBOT has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the market expecting BBOT stock to perform?
12 analysts have analysed BBOT and the average price target is 24.48 USD. This implies a price increase of 86.3% is expected in the next year compared to the current price of 13.14.
What sector and industry does BRIDGEBIO ONCOLOGY THERAPEUT belong to?
BRIDGEBIO ONCOLOGY THERAPEUT (BBOT) operates in the Health Care sector and the Biotechnology industry.
Would investing in BRIDGEBIO ONCOLOGY THERAPEUT be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BBOT.
BBOT Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to BBOT.
BBOT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BBOT. While BBOT seems to be doing ok healthwise, there are quite some concerns on its profitability.
BBOT Financial Highlights
Over the last trailing twelve months BBOT reported a non-GAAP Earnings per Share(EPS) of 0.2. The EPS increased by 17.4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | 2.39% | ||
| ROE | 2.49% | ||
| Debt/Equity | 0 |
BBOT Forecast & Estimates
12 analysts have analysed BBOT and the average price target is 24.48 USD. This implies a price increase of 86.3% is expected in the next year compared to the current price of 13.14.